Skip to content

Clinical Trials

Deep Brain Stimulators Clinical Trial Analysis

 

Publication Date July 2009
Publisher Global Markets Direct
Product Type
Pages 47
ISBN Number not applicable
Product Code GMD02881

Price

£660.00
approximately: $999 | €737

pdf

Buy Now

Order above formats by FAX

Order by Fax

Summary

Global Markets Direct's "Deep Brain Stimulators Clinical Trials Analysis" is an essential source of data and information pertaining to product clinical trials being carried out by Deep Brain Stimulators manufacturers, globally. The report provides exhaustive information on each clinical investigation study with coverage detailed coverage on the pipeline products these trials are being carried out for.

Scope

  • The report provides analysis and review of the key clinical trials being carried out globally and across key Deep Brain Stimulators market categories - Deep Brain Stimulators
  • The report covers information on each product being clinically tested with detailed coverage on the pipeline product profile, the indication it's being investigated for etc.
  • The report provides an in-depth analysis of the clinical trials with information on trial phase, trial 0status, trial acronym, purpose, inclusion and exclusion criteria, description, design, intervention, investigator information, primary and secondary end-points and trial results
  • The report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by Global Markets Direct's team of industry experts.

Reasons to Buy

  • Effectively plan your Mergers and Acquisitions and partnership strategies by identifying companies with the most promising pipeline.
  • Stay ahead of the information curve in the fast changing Deep Brain Stimulators market.
  • Plan in-licensing and out-licensing opportunities through review of pipeline products and technologies.
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Proactively plan and execute your competitive strategies by identifying clinical trials status of the leading competitive products in pipeline.
  • Stay ahead of competition by understanding the changing competitive landscape in specific geographies.

Contents

  • 1 List of Tables
  • 1.2 List of Figures
  • 2 Deep Brain Stimulators Clinical Trials
    • 2.1 Deep Brain Stimulators Clinical Trial By Equipment Type
    • 2.2 Deep Brain Stimulators Clinical Trials By Trial Phase and Trial Status
    • 2.3 Deep Brain Stimulators Pipeline Products By Development Stage
    • 2.4 Deep Brain Stimulators Pipeline Products By Therapy Area
    • 2.5 Deep Brain Stimulators Pipeline Products By News Summary
    • 2.6 Deep Brain Stimulators Reclaim for Depression
      • 2.6.1 Deep Brain Stimulation of the Internal Capsule for Severe and Medically Refractory Major Depression
      • 2.6.2 Prospective,Randomised, Double-Blind, Multicenter Study To Assess The Efficacy And Safety Of Bilateral Globus Pallidus Internus -In Patients With Medically Refractory Primary Cervical Dystonia
      • 2.6.3 Randomisierte, Doppelblinde Langzeitstudie Zur Klinischen Wirksamkeit Der Bilateralen Globus Pallidus Internus-Stimulation Bei Idiopathischer Generalisierter Oder Segmentaler Dystonie
      • 2.6.4 Deep Brain Stimulation For Treatment-Refractory Major Depression
      • 2.6.5 Investigation Of Efficacy And Safety Of Deep Brain Stimulation Of The Cingulate Cortex In Patients With Treatment Resistant Major Depression
      • 2.6.6 Reclaim Deep Brain Stimulation Clinical Study For Treatment-Resistant Depression
    • 2.7 Deep Brain Stimulators Renova-DT Cortical Stimulation System
      • 2.7.1 Feasibility Study of the Safety and Effectiveness of Cortical Stimulation for Subjects With Major Depressive Disorder
    • 2.8 Deep Brain Stimulators Intercept Epilepsy Control System
      • 2.8.1 SANTE - Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy
    • 2.9 -Deep Brain Stimulators Deep TMS H System
      • 2.9.1 Evaluation of the H-Coil Transcranial Magnetic Stimulation(TMS) Device- Augmentation for Drug Resistant Depression
      • 2.9.2 Evaluation of the novel Deep TMS technique in the treatment of Post traumatic stress disorder resistant to pharmacological or psychological treatment
      • 2.9.3 Evaluation of the novel deep TMS Coil designs as an augmentation measure in the treatment of medication-resistant major depression
      • 2.9.4 Phase 2 (Feasibility) Study Of Transcranial Magnetic Stimulation As Additional Therapy To Drug Treatment In Patients With Alzheimer's Disease
      • 2.9.5 Phase 2 Double Blind Randomized Clinical Trial Of Deep Transcranial Magnetic Stimulation After Stroke
      • 2.9.6 Evaluation Of The H1 Coil And H2 Coil TMS Device - Safety And Feasibility In Major Depression Episode
    • 2.10 Deep Brain Stimulators Magstim Rapid
      • 2.10.1 The Antidepressant Effect Of Right Temporal Kow Frequency rTMS Compared To Sham. A Clinical Controlled, Randomized, Blinded Study
      • 2.10.2 Re-Enrollment Bilateral rTMS Clinical Trial for Persistent Auditory Hallucinations
    • 2.11 Deep Brain Stimulators Libra Deep Brain Stimulation System
      • 2.11.1 A Clinical Evaluation of Bilateral Stimulation of the Subthalamic Nucleus (STN) Using the ANS Totally Implantable Deep Brain Stimulation System as an Adjunctive Treatment for Reducing Some of the Symptoms of Advanced, Levodopa-Responsive Parkinson's Disease That Are Not Adequately Controlled With Medication
      • 2.11.2 Clinical Study To Evaluate A Non-Pharmacological Device
      • 2.11.3 Subthalamic Nucleus (STN) Deep Brain Stimulation (DBS) In Patients With Cranial And Cervical Dystonia
  • 3 Recent Developments
    • 3.1 Product News
      • 3.1.1 Jun 08, 2009: St. Jude Medical Announces Completion Of Patient Implants In US Pivotal Study Of DBS For Parkinson's Disease
      • 3.1.2 May 21, 2009: Medtronic Announces Approval Of Activa RC And Activa PC Devices For Patients With Movement Disorders In US
      • 3.1.3 May 21, 2009: St. Jude Releases Results Of The Libra DBS Canadian Study
      • 3.1.4 Feb 19, 2009: Reclaim Deep Brain Stimulation (DBS) Therapy Of Medtronic Receives FDA HDE Approval For A Psychiatric Indication
      • 3.1.5 Feb 11, 2009: Surgeons At UT Southwestern Medical Center Performs First Local Implant In Deep Brain Stimulation Study For Depression
      • 3.1.6 Dec 08, 2008: Data From Pivotal Study Show Medtronic Deep Brain Stimulation Therapy Reduced Seizure Rate In Patients With Severe Epilepsy
      • 3.1.7 Oct 14, 2008: Northstar Neuroscience Receives FDA Approval For A Clinical Study Of Its Cortical Stimulation System For The Treatment Of Major Depressive Disorder
      • 3.1.8 Oct 08, 2008: FDA Clears Neuronetics's NeuroStar TMS Therapy For The Treatment Of Depression
      • 3.1.9 Jun 15, 2007: Neurostar Tms Therapy Produced Significant Improvements In Depression Symptoms In Recently-Published Randomized, Controlled Trial
      • 3.1.10 Jun 15, 2007: Neurostar TMS Therapy Produced Significant Improvements In Depression Symptoms In Recently-Published Randomized, Controlled Trial
    • 3.2 Product Approvals
      • 3.2.1 May 21, 2009: Medtronic Announces Approval Of Activa RC And Activa PC Devices For Patients With Movement Disorders In US
      • 3.2.2 Feb 19, 2009: Reclaim Deep Brain Stimulation (DBS) Therapy Of Medtronic Receives FDA HDE Approval For A Psychiatric Indication
      • 3.2.3 Oct 08, 2008: FDA Clears Neuronetics's NeuroStar TMS Therapy For The Treatment Of Depression
    • 3.3 Clinical Trials
      • 3.3.1 Jun 08, 2009: St. Jude Medical Announces Completion Of Patient Implants In US Pivotal Study Of DBS For Parkinson's Disease
      • 3.3.2 May 21, 2009: St. Jude Releases Results Of The Libra DBS Canadian Study
      • 3.3.3 Feb 11, 2009: Surgeons At UT Southwestern Medical Center Performs First Local Implant In Deep Brain Stimulation Study For Depression
      • 3.3.4 Dec 08, 2008: Data From Pivotal Study Show Medtronic Deep Brain Stimulation Therapy Reduced Seizure Rate In Patients With Severe Epilepsy
      • 3.3.5 Oct 14, 2008: Northstar Neuroscience Receives FDA Approval For A Clinical Study Of Its Cortical Stimulation System For The Treatment Of Major Depressive Disorder
  • 4 Appendix
    • 4.1 Methodology
      • 4.1.1 Coverage
      • 4.1.2 Secondary Research
      • 4.1.3 Primary Research
      • 4.1.4 Expert Panel Validation
    • 4.2 Contact Us
    • 4.3 About Global Markets Direct
    • 4.4 Disclaimer
  • 1 List of Tables
    • Table 1: Deep Brain Stimulators Clinical Trial By Equipment Type
    • Table 2: Deep Brain Stimulators Clinical Trials By Trial Phase and Trial Status
    • Table 3: Deep Brain Stimulators Pipeline Products By Development Stage
    • Table 4: Deep Brain Stimulators Pipeline Products By Therapy Area
    • Table 5: Deep Brain Stimulators Pipeline Products By News Summary
    • Table 6: Reclaim for Depression - Deep Brain Stimulation of the Internal Capsule for Severe and Medically Refractory Major Depression
    • Table 7: Reclaim for Depression - Prospective,Randomised, Double-Blind, Multicenter Study To Assess The Efficacy And Safety Of Bilateral Globus Pallidus Internus -In Patients With Medically Refractory Primary Cervical Dystonia
    • Table 8: Reclaim for Depression - Randomisierte, Doppelblinde Langzeitstudie Zur Klinischen Wirksamkeit Der Bilateralen Globus Pallidus Internus-Stimulation Bei Idiopathischer Generalisierter Oder Segmentaler Dystonie
    • Table 9: Reclaim for Depression - Deep Brain Stimulation For Treatment-Refractory Major Depression
    • Table 10: Reclaim for Depression - Investigation Of Efficacy And Safety Of Deep Brain Stimulation Of The Cingulate Cortex In Patients With Treatment Resistant Major Depression
    • Table 11: Reclaim for Depression - Reclaim Deep Brain Stimulation Clinical Study For Treatment-Resistant Depression
    • Table 12: Renova-DT Cortical Stimulation System - Feasibility Study of the Safety and Effectiveness of Cortical Stimulation for Subjects With Major Depressive Disorder
    • Table 13: Intercept Epilepsy Control System - SANTE - Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy
    • Table 14: Deep TMS H System - Evaluation of the H-Coil Transcranial Magnetic Stimulation(TMS) Device- Augmentation for Drug Resistant Depression
    • Table 15: Deep TMS H System - Evaluation of the novel Deep TMS technique in the treatment of Post traumatic stress disorder resistant to pharmacological or psychological treatment
    • Table 16: Deep TMS H System - Evaluation of the novel deep TMS Coil designs as an augmentation measure in the treatment of medication-resistant major depression
    • Table 17: Deep TMS H System - Phase 2 (Feasibility) Study Of Transcranial Magnetic Stimulation As Additional Therapy To Drug Treatment In Patients With Alzheimer's Disease
    • Table 18: Deep TMS H System - Phase 2 Double Blind Randomized Clinical Trial Of Deep Transcranial Magnetic Stimulation After Stroke
    • Table 19: Deep TMS H System - Evaluation Of The H1 Coil And H2 Coil TMS Device - Safety And Feasibility In Major Depression Episode
    • Table 20: Magstim Rapid - The Antidepressant Effect Of Right Temporal Kow Frequency rTMS Compared To Sham. A Clinical Controlled, Randomized, Blinded Study
    • Table 21: Magstim Rapid - Re-Enrollment Bilateral rTMS Clinical Trial for Persistent Auditory Hallucinations
    • Table 22: Libra Deep Brain Stimulation System - A Clinical Evaluation of Bilateral Stimulation of the Subthalamic Nucleus (STN) Using the ANS Totally Implantable Deep Brain Stimulation System as an Adjunctive Treatment for Reducing Some of the Symptoms of Advanced, Levodopa-Responsive Parkinson's Disease That Are Not Adequately Controlled With Medication
    • Table 23: Libra Deep Brain Stimulation System - Clinical Study To Evaluate A Non-Pharmacological Device
    • Table 24: Libra Deep Brain Stimulation System - Subthalamic Nucleus (STN) Deep Brain Stimulation (DBS) In Patients With Cranial And Cervical Dystonia
  • 1.2 List of Figures
    • Figure 1: Global Markets Direct Methodology